Background/Objectives: Several studies have demonstrated the positive clinical and
functional impact of adding Long-Acting Muscarinic Antagonist (LAMA) to Inhaled …

Small airway disease is recognized as a cardinal pathological process of chronic obstructive
pulmonary disease (COPD), and recently small airways have been recognized as a major …

Patients with asthma who are suboptimally responsive to inhaled corticosteroids (ICS) and
long-acting β 2-agonists (LABAs) are frequently exposed to oral corticosteroids and high …

Background Inflammation in small airways is particularly clinically active in severe asthma
but they still continue to be ignored as considered silent. Recently, the Atlantis study reports …

A growing number of clinical trials are documenting that adding a long-acting muscarinic
antagonist (LAMA) to established asthma treatment with an inhaled corticosteroid (ICS) and …

Asthma affects nearly 340 million people worldwide and over 50% of patients have mild
asthma. The goals of treatment are to improve day-to-day asthma symptom control and to …

Objective Long-acting muscarinic antagonists (LAMAs) have been used in the treatment of
obstructive pulmonary diseases for years. Long-acting muscarinic antagonists were …

BACKGROUND: Whether small airways dysfunction persists in patients with asthma
receiving standard community treatment is unknown. Impulse oscillometry (IOS) is a …

Asthma is a common chronic airways disease with significant impact on patients, caregivers,
and the health care system. Although most research and novel interventions mainly have …

Management of mild asthma has undergone a paradigm shift in recent years. Mild
intermittent asthma has classically been treated with short-acting bronchodilators (primarily …